Polymer Therapeutics

Peppe J, Porzio A, Davidson DM. 2008. A new formulation of tolevamer, a novel nonantibiotic polymer, is safe and well-tolerated in healthy volunteers: a randomized phase I trial. Br J Clin Pharmacol.

Barker RHJ, Dagher R, Davidson DM, Marquis JK. 2006. Review article: Tolevamer, a novel toxin-binding polymer: overview of preclinical pharmacology and physicochemical properties. Aliment Pharmacol Ther 24:1525-1534.

Duggal A, Hanus M, Zhorov E, Dagher R, Plone MA, Goldberg J, Burke SK. 2006. Novel dosage forms and regimens for sevelamer-based phosphate binders. J Ren Nutr 16:248-252.

Hanus M, Zhorov E. 2006. Bile acid salt binding with colesevelam HCl is not affected by suspension in common beverages. J Pharm Sci 95:2751-2759.

Marquis JK, Dagher R, Baker BA, Jones MR. 2006. Colesevelam hydrochloride does not cause maternal or fetal toxicity in rats and rabbits. Reprod Tox 21:197-207.

Polomoscanik SC, Cannon CP, Neenan TX, Holmes-Farley SR, Mandeville WH, Dhal PK. 2005. Hydroxamic acid-containing hydrogels for nonabsorbed iron chelation therapy: synthesis, characterization, and biological evaluation. Biomacromole 6:2946-2953.

Donovan JM, Von Bergmann K, Setchell KD, Isaacsohn J, Pappu AS, Illingworth DR, Olson T, Burke SK. 2005. Effects of colesevelam HC1 on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. Dig Dis Sci 50:1232-1238.

Ferramosca E, Burke S, Chasan-Taber S, Ratti C, Chertow GM, Raggi P. 2005. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J 149:820-825.

Garg JP, Chasan-Taber S, Blair A, Plone M, Bommer J, Raggi P, Chertow GM. 2005. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. Arthritis Rheum 52:290-295.

Braunlin W, Xu Q, Hook P, Fitzpatrick R, Klinger JD, Burrier R, Kurtz CB. 2004. Toxin binding of tolevamer, a polyanionic drug that protects against antibiotic-associated diarrhea. Biophys J 87:534-539.

Burke SK. 2004. Arterial calcification in chronic kidney disease. Semin Nephrol 24:403-407.

Huval CC, Chen X, Holmes-Farley SR, Mandeville WH, Polomoscanik SC, Sacchiero RJ, Dhal PK. 2004. Molecularly imprinted bile acid sequestrants: synthesis and biological studies. Mat Res Soc Sym Proc 787:85-90.

Huval CC, Holmes-Farley SR, Mandeville WH, Sacchiero R, Dhal PK. 2004. Syntheses of hydrophobically modified cationic hydrogels by copolymerization of alkyl substituted diallylamine monomers and their use as bile acid sequestrants. Eu Polymer J 40:693-701.

Huval CC, Holmes-Farley SR, Mandeville WH, Petersen JS, Sacchiero RJ, Maloney C, Dhal PK. 2004. Ammonium and guanidinium functionalized hydrogels as bile acid sequestrants: Synthesis, characterization, and biological properties. J Macromole Sci Pure & App Chem A41:231-244.

Marquis JK, Dagher R, Jones M. 2004. Dietary administration of colesevelam hydrochloride does not affect fertility or reproductive performance in rats. Int J Toxicol 23:357-367.

Swearingen RA, Zhorov E, Cohen A, Sybertz T, Barry EF. 2004. Determination of the binding parameter constants of Renagel capsules and tablets at pH 7 by high performance capillary electrophoresis. J Pharma & Biomed Anal 35:753-760.

Zhang B, Krull IS, Cohen A, Smisek DL, Kloss A, Wang B, Bourque AJ. 2004. Separation of quaternary ammonium diastereomeric oligomers by capillary electrophoresis. J Chromatogr A 1034:213-220.

Burke SK, Dillon MA, Hemken DE, Rezabek MS, Balwit JM. 2003. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients. Adv in Renal Replac Ther 10:133-145.

Chertow GM, Raggi P, McCarthy JT, Schulman G, Silberzweig J, Kuhlik A, Goodman WG, Boulay A, Burke SK, Toto RD. 2003. The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. Am J Nephrol 23:307-314.

Cozzolino M, Staniforth ME, Liapis H, Finch J, Burke SK, Dusso AS, Slatopolsky E. 2003. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int 64:1653-1661.

Katsumata K, Kusano K, Hirata M, Tsunemi K, Nagano N, Burke SK, Fukushima N. 2003. Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats. Kidney Int 64:441-450.

Nagano N, Miyata S, Obana S, Kobayashi N, Fukushima N, Burke SK, Wada M. 2003. Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency. Nephrol Dial Transplant 18:2014-2023.

Amin N. 2002. The impact of improved phosphorus control: Use of sevelamer hydrochloride in patients with chronic renal failure. Nephrol Dial Transplant 17:340-345.

Braunlin W, Zhorov E, Guo A, Apruzzese W, Xu Q, Hook P, Smisek DL, Mandeville WH, Holmes-Farley SR. 2002. Bile acid binding to sevelamer HCl. Kidney Int 62:611-619.

Chertow GM, Burke SK, Raggi P. 2002. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245-252.

Cozzolino M, Dusso AS, Liapis H, Finch J, Lu Y, Burke SK, Slatopolsky E. 2002. The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats. J Am Soc Nephrol 13:2299-2308.

Donovan JM, Kisicki JC, Stiles MR, Tracewell WG, Burke SK. 2002. Effect of colesevelam on lovastatin pharmacokinetics. Ann Pharmacother 36:392-397.

Plone MA, Petersen JS, Rosenbaum DP, Burke SK. 2002. Sevelamer, a phosphate-binding polymer, is a non-absorbed compound. Clin Pharmacokinet 41:517-523.

Swearingen RA, Chen X, Petersen JS, Riley KS, Wang D, Zhorov E. 2002. Determination of the binding parameter constants of Renagel capsules and tablets utilizing the Langmuir approximation at various pH by ion chromatography. J Pharm Biomed Anal 29:195-201.

Booker M. 2001. S-8921 (Shionogi). Curr Opin Investig Drugs 2:393-395.

Burke S, Amin N, Incerti C, Plone M, Watson N. 2001. Sevelamer hydrochloride (Renagel), a nonabsorbed phosphate-binding polymer, does not interfere with digoxin or warfarin pharmacokinetics. J Clin Pharmacol 41:193-198.

Burke SK, Amin NS, Incerti C, Plone MA, Lee JW. 2001. Sevelamer hydrochloride (Renagel), a phosphate-binding polymer, does not alter the pharmacokinetics of two commonly used antihypertensives in healthy volunteers. J Clin Pharmacol 41:199-205.

Davidson MH, Toth P, Weiss S, McKenney J, Hunninghake D, Isaacsohn J, Donovan JM, Burke SK. 2001. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin Cardiol 24:467-474.

Hunninghake D, Insull W, Jr., Toth P, Davidson D, Donovan JM, Burke SK. 2001. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis 158:407-416.

Knapp HH, Schrott H, Ma P, Knopp R, Chin B, Gaziano JM, Donovan JM, Burke SK, Davidson MH. 2001. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 110:352-360.

Kurtz CB, Cannon EP, Brezzani A, Pitruzzello M, Dinardo C, Rinard E, Acheson DW, Fitzpatrick R, Kelly P, Shackett K, Papoulis AT, Goddard PJ, Barker RH, Jr., Palace GP, Klinger JD. 2001. GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis. Antimicrob Agents Chemother 45:2340-2347.

Nagano N, Miyata S, Obana S, Eto N, Fukushima N, Burke SK, Wada M. 2001. Renal mineral handling in normal rats treated with sevelamer hydrochloride (Renagel), a noncalcemic phosphate binder. Nephron 89:321-328.

Nagano N, Miyata S, Obana S, Ozai M, Kobayashi N, Fukushima N, Burke SK, Wada M. 2001. Sevelamer hydrochloride (Renagel), a non-calcaemic phosphate binder, arrests parathyroid gland hyperplasia in rats with progressive chronic renal insufficiency. Nephrol Dial Transplant 16:1870-1878.

Palace GP, Lazari P, Norton K. 2001. Analysis of the physicochemical interactions between Clostridium difficile toxins and cholestyramine using liquid chromatography with post-column derivatization. Biochim Biophys Acta 1546:171-184.